Last reviewed · How we verify
Electrofusion DC vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Electrofusion DC vaccine (Electrofusion DC vaccine) — Beth Israel Deaconess Medical Center. Fuses patient dendritic cells with tumor cells using electrofusion to create a personalized vaccine that activates T-cell responses against cancer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Electrofusion DC vaccine TARGET | Electrofusion DC vaccine | Beth Israel Deaconess Medical Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Electrofusion DC vaccine CI watch — RSS
- Electrofusion DC vaccine CI watch — Atom
- Electrofusion DC vaccine CI watch — JSON
- Electrofusion DC vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Electrofusion DC vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/electrofusion-dc-vaccine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing